2. Search Result
Search Result
Results for "

Immune rejection

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

5

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-401475
    Protein kinase inhibitor 9

    		PKC Cardiovascular Disease Inflammation/Immunology Cancer
    Protein kinase inhibitor 9 (Compound example 175) is an inhibitor of serine/threonine and tyrosine kinase activity. Protein kinase inhibitor 9 can be used for the research of cancer, hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders .
    Protein kinase inhibitor 9
  • HY-P99257
    Bleselumab

    ASKP 1240

    		 TNF Receptor Inflammation/Immunology
    Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
    Bleselumab
  • HY-157746
    CTPS1-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology Cancer
    CTPS1-IN-1 (compound R80) is a CTPS1 inhibitor. CTPS1-IN-1 has the potential to research cancer (such as promoting vascular injury or surgical recovery) and immune system diseases (such as rejection of transplanted cells and tissues, transplant-related diseases or disorders, allergies, and autoimmune diseases) .
    CTPS1-IN-1
  • HY-P99488
    Briquilimab

    JSP-191; AMG-191

    		 c-Kit Inflammation/Immunology Cancer
    Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
    Briquilimab
  • HY-P99152
    Muromonab

    Muromanab-CD3

    		 CD3 Interleukin Related IFNAR Inflammation/Immunology Cancer
    Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
    Muromonab
  • HY-32340
    Lexacalcitol

    KH1060

    		 VD/VDR Inflammation/Immunology Cancer
    Lexacalcitol (KH1060), a vitamin D analog, is a potent regulator of cell growth and immune responses. Lexacalcitol can be used for the research of graft rejection, psoriasis, cancer and auto-immune diseases .
    Lexacalcitol
  • HY-N9753
    Tsukubamycin B

    		Others
    Tsukubamycin B is discovered from Streptomyces tsukubaensis and exhibits immunosuppressive activity by inhibiting T-cell activation. Tsukubamycin B can be used for immune rejection reaction research .
    Tsukubamycin B
  • HY-P991557
    ABI793

    		TNF Receptor Inflammation/Immunology
    ABI793 is a human IgG1 anti-human CD154 (CD40 ligand) monoclonal antibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
    ABI793
  • HY-155100
    BI 7446

    		STING Inflammation/Immunology Cancer
    BI 7446 is a cyclic dinucleotide (CDN)-based potent and selective stimulator of interferon genes (STING) agonist. BI 7446 can activate all five STING variants in cells and induce tumor-specific immune-mediated tumor rejection. BI 7446 can be used for immuno-oncology research .
    BI 7446
  • HY-162490
    TF-S14

    		ROR Inflammation/Immunology
    TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .
    TF-S14
  • HY-P990801
    Anti-Mouse CD11a/LFA-1α Antibody (M17/4)

    		Integrin Parasite Bacterial Infection Neurological Disease Inflammation/Immunology Cancer
    Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonal antibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
    Anti-Mouse CD11a/LFA-1α Antibody (M17/4)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: